Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Entrectinib by F. Hoffmann-La Roche for Metastatic Pancreatic Cancer: Likelihood of Approval
Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Pancreatic Cancer. According to...
Entrectinib by F. Hoffmann-La Roche for Neuroblastoma: Likelihood of Approval
Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Neuroblastoma. According to GlobalData, Phase...
Entrectinib by F. Hoffmann-La Roche for Renal Cell Carcinoma: Likelihood of Approval
Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Renal Cell Carcinoma. According to...
Entrectinib by F. Hoffmann-La Roche for Metastatic Uveal Melanoma: Likelihood of Approval
Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Uveal Melanoma. According to...